About 

Ultime notizie per CIMG (NASDAQ:IMG) Azioni

CIMG

Nuzee

CIMG Inc is a coffee and technologies company. The company is a co-packer of single-serve pour-over coffee, coffee brew bags and Dripkits. The company's brand portfolio includes Coffee Blenders, Twin Peaks, Active Cup, Relax Cup, Think Cup, Nude Cup, Pine Ranch Coffee, and Dripkit. Its geographical segments are North America, which accounts for the majority of revenue; and South Korea.

News

SMTK

Smartkem Enters Preliminary Joint Development Agreement With Manz Asia To Co-Develop Dielectric Ink Solutions For AI Chip Packaging

Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today&nbsp;announced that John Houston, Ph.D., Chairperson, Chief Executive Officer (CEO) and President at Arvinas, has informed the Board of Directors of his plans to retire from his role as President and CEO following a search for, and the appointment of, the Company's new CEO. The Arvinas Board of Directors has begun a search for a new CEO, and Dr. Houston will remain Chairperson of Arvinas' Board of Directors upon retiring as President and CEO.
"On behalf of the Arvinas Board of Directors, I sincerely thank John for his exceptional leadership and significant contributions to Arvinas over the past 8 years and his commitment to a smooth transition as we identify his successor," said Briggs Morrison, M.D., Arvinas Board Member and Lead Independent Director. "John has guided Arvinas through a substantial number of ‘firsts' for PROTACs in the industry, from the first to enter the clinic to the first positive pivotal Phase 3 trial and the first new drug application. John and Arvinas have turned targeted protein degradation into a well-known modality across several therapeutic areas. Due to his efforts, the Company is well positioned to benefit many patients in the years to come. As we undertake the process of identifying a new CEO, the Board is committed to conducting a thoughtful search to ensure continued strong leadership. We look forward to continuing our work with John in his capacity as Chairperson."
With more than 35 years of experience in the pharmaceutical and biotech industries, Dr. Houston joined Arvinas in January 2017 as President of Research and Development and Chief Scientific Officer responsible for leading the discovery, translational, and early clinical development research efforts. In September 2017, Dr. Houston was appointed President and CEO, and in 2023 he was named Arvinas' Chairperson.
During his tenure as CEO, Dr. Houston has been instrumental in Arvinas' success moving six programs into the clinic, reporting the results of the first positive pivotal Phase 3 trial for a PROTAC, and reporting for the first time that an orally administered PROTAC can achieve pharmacodynamic activity in the central nervous system.
"It has been an honor to lead Arvinas alongside incredibly talented colleagues and a supportive Board of Directors," said Dr. Houston. "I look forward to remaining a part of Arvinas as Chairperson and I'm confident in the Company's ability to improve the lives of patients with serious diseases through our revolutionary PROTAC protein degradation platform. From initiating the first oral PROTAC degrader in clinical trials to delivering positive topline results, it is evident that Arvinas has and will continue to push the boundaries of what's possible."

Management

ARVN

Arvinas Begins CEO Search as Longtime Leader John Houston Plans Exit From Top Role, Will Stay On as Board Chair

– Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH Dispensed applicator units in Q2 2025 –
– Company reports receipt of $8 million milestone payment from its Japanese development partner, Torii Pharmaceutical, for initiation of global Phase 3 program in common warts –

VRCA

Verrica Reports Record 13,434 YCANTH Applicator Units Dispensed In Q2 2025, Marking 32.8% Sequential Growth

B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) ("B. Riley" or the "Company"), a diversified financial services company, today announced that it has entered into an amendment to its senior secured credit agreement ("Term Loan Facility") with funds managed by Oaktree Capital Management, L.P. ("Oaktree").
The amended Term Loan Facility provides incremental flexibility, including: a new investment basket that enables an incremental $100m to facilitate transactions using B. Riley Financial's balance sheet; a $30 million investment basket for parent company investments upsized from $20 million; and the ability to deploy up to $25 million of cash to reduce other indebtedness, including through the potential repurchase of the Company's unsecured notes.

Financing

RILY

B. Riley Financial Enters Amendment To Senior Credit Facility With Oaktree; Amendment Increases Operational Flexibility, Outstanding Balance Reduced To $62.5M

TD Cowen analyst John Blackledge maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $700 to $800.

Price Target

Analyst Ratings

TD Cowen Maintains Buy on Meta Platforms, Raises Price Target to $800

SES AI Unveils Deep Space In MU-0.5, Enabling Senior Scientist-Level Battery R&D In Minutes With Agentic AI

KB801 is a redosable eye drop gene therapy in development for the treatment of NK, a degenerative corneal disease characterized by damage or loss of function in the neurons innervating the eye leading to corneal epithelial defects, ulcers, and perforation. Left untreated, NK can result in severe vision loss. Although NK is a rare disease with an estimated prevalence in the range of 10 to 50 cases per 100,000, claims data analyses suggest awareness and diagnosis rates are on the rise in the United States. Based on available claims data, an estimated 68,000 patients in the United States had a NK claim in 2024, up over 115% from 31,000 patients with a NK claim in 2020.

Biotech

Health Care

General

KRYS

Krystal Biotech Has Dosed The First Patient In Its Phase 1/2 EMERALD-1 Trial Evaluating KB801 For Neurotrophic Keratitis

ALMU

Aeluma Expands Defense And Aerospace Footprint WIth NASA and Navy Contracts To Develop Quantum And Imaging Solutions

WIIM

SUGP

SU Group shares are trading higher after the company was awarded an HK$88.5 million hospital contract.

<a href="https://www.globenewswire.com/Tracker?data=qSKG7PuFQ0rZwMGe7WKrlkgJKEdXTpfI-J47iNso5ZwkFSDclvDIdErYfU-4e7-YFLtOOCQFSliIy3SSK403TVPuOL1aTiPsvziexJm7sZg=">Plug Power Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>), a global leader in comprehensive hydrogen solutions, today announced a new multi-year enhanced supply agreement with a leading U.S.-based industrial gas company and longtime hydrogen partner through 2030. The agreement extends the companies' current strategic relationship through 2030, securing reliable hydrogen supply for Plug's growing applications business while significantly reducing the cost structure and improving cash flows. As part of the extension, the strategic partner will continue to supply Plug with liquid hydrogen while immediately reducing the cost and collaborating on improved network efficiency. The extension aligns with Plug's strategic objectives to strengthen margins, enhance operational flexibility and support customer demand across a growing base of over 275 hydrogen-consuming customer sites and growing. &nbsp;

PLUG

Plug Power Secures Long-Term Hydrogen Deal Through 2030 to Cut Costs and Boost Cash Flow

Contracts

SU Group Awarded HK$88.5M Hospital Contract

Fury Gold Mines Limited (NYSE:<a href="https://www.benzinga.com/stock/FURY#NYSE">FURY</a>) ("Fury" or the "Company") is pleased to announce drill results from the maiden drill program, totaling 825 metres (m) in 5 holes, on its Ninaaskumuwin lithium discovery at the Elmer East project located in the Eeyou Istchee James Bay region of Quebec (Figure 1). The drilling targeted a spodumene-bearing pegmatite outcrop, which returned surface samples of up to 3.92% Li2O. Highlights from the drill campaign include 32.35m of 1.16% Li2O from EE24-003 and 22.48m of 1.19% Li2O from EE24-002 (Table 1). The lithium mineralized spodumene-bearing pegmatite remains open at depth and along strike, warranting additional drilling.
Highlights:
<ul>
<li>Thick spodumene-bearing pegmatite (&gt;32 m in thickness) was intersected in three holes with individual sample grades of up to 3.70% Li2O;</li>
<li>Drill results confirm the vertical continuity of lithium mineralization to 150 m below surface; and</li>
<li>The lithium-bearing pegmatite remains open along strike and to depth.</li>
</ul>

FURY

Fury Gold Uncovers High-Grade Lithium in Quebec—Drill Results Show Up to 3.70% Li2O, More Exploration Ahead

NSPR

InspireMD Announces US Commercial Launch Of CGuard Prime Carotid Stent System For Stroke Prevention

Redburn Atlantic analyst Chris Pitcher upgrades Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) from Sell to Neutral and lowers the price target from $40 to $30.

Upgrades

BF/B

Redburn Atlantic Upgrades Brown-Forman to Neutral, Lowers Price Target to $30

<a href="https://www.modernretail.co/marketing/exclusive-snapchat-taps-american-eagle-as-a-snap-map-ad-partner-ahead-of-back-to-school-season/" title="https://www.modernretail.co/marketing/exclusive-snapchat-taps-american-eagle-as-a-snap-map-ad-partner-ahead-of-back-to-school-season/">https://www.modernretail.co/marketing/exclusive-snapchat-taps-american-eagle-as-a-snap-map-ad-partner-ahead-of-back-to-school-season/</a>

SNAP

Modern Retail Reported Earlier. American Eagle To Become The First Specialty Fashion Brand To Highlight Its Store Locations And Brand-related Content On Snapchat's Snap Map

Redburn Atlantic analyst Charlie Higgs downgrades Monster Beverage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) from Buy to Neutral and lowers the price target from $63 to $60.

Downgrades

MNST

Redburn Atlantic Downgrades Monster Beverage to Neutral, Lowers Price Target to $60

Wedbush analyst Martin Fan initiates coverage on Cartesian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) with a Outperform rating and announces Price Target of $38.

Initiation

RNAC

Wedbush Initiates Coverage On Cartesian Therapeutics with Outperform Rating, Announces Price Target of $38

The conversational artificial intelligence (AI) company SoundHound AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) surged over 11% on Tuesday after having the second-highest volume day of 2025. With several positive technical indicators, this particular momentum signaled that the stock may be overbought.
What Happened: As the demand for AI is skyrocketing in every sector, the voice AI company SoundHound had its second-highest day of trading volume at 118,340,200 on Tuesday, July 6, with Feb. 14 being the highest at 177,289,100.
Traders remained positive on the stock as Ryan Collins, the Florida Director for StepStone Group, reaffirmed his prediction of a &#8220;break through&#8221; beyond $12.6 apiece.
The stock rose 11.69% to end at 12.71% on Tuesday. Collins also cautioned that the stock may undergo some pressure around $14 apiece.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SOUN&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SOUN</a> I told you yesterday that it will break through the high point near $12.6. There is a certain gap pressure near $14, which is our first profit target. Congratulations to those who followed up and bought yesterday. <a href="https://t.co/ISIcuuEKxL">pic.twitter.com/ISIcuuEKxL</a>
&mdash; Top Stock Recommendations Ryan Collins (@RyanCapital_) <a href="https://twitter.com/RyanCapital_/status/1942586070312644616?ref_src=twsrc%5Etfw">July 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, online financial commentator, Tiger Line Trading predicted a surge to $15 per share of the stock.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SOUN&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SOUN</a> NEXT BIG LEVEL AT $15.00!! <a href="https://t.co/rskl8TJfZU">pic.twitter.com/rskl8TJfZU</a>
&mdash; Tiger Line Trading (@TigerLineTrades) <a href="https://twitter.com/TigerLineTrades/status/1942584085525979280?ref_src=twsrc%5Etfw">July 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
As per the <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data, SoundHound AI stock was above its short and long-term moving averages, signaling a bullish stock trend.
Its MACD line was also positive and above its signal line, suggesting a potential bullish trend, with its 12-week exponential moving average being above its 26-week EMA.
However, its relative strength index at 71.58 meant that the stock was in the overbought zone, hinting at a potential slowdown or reversal in the near term.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09064414/SOUN-technical-chart-1024x576.png" alt="" class="wp-image-978133" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09064414/SOUN-technical-chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09064414/SOUN-technical-chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09064414/SOUN-technical-chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09064414/SOUN-technical-chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09064414/SOUN-technical-chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46313514/warren-buffetts-quiet-dividend-play-9-high-yield-stocks-held-by-a-berkshire-subsidiary">Warren Buffett&#8217;s Quiet Dividend Play: 9 High-Yield Stocks Held By A Berkshire Subsidiary</a>
Why It Matters: Fundamentally, during its <a href="https://www.benzinga.com/news/earnings/25/05/45302790/soundhound-ai-stock-slides-on-mixed-q1-results-reaffirms-fy25-outlook">first quarter earnings</a> call, CFO Nitesh Sharan reaffirmed the company's 2025 revenue guidance of $157 to $177 million, despite a $2 million adverse impact from a customer's change of control. 
He also highlighted the i<a href="https://www.benzinga.com/25/05/45316296/soundhounds-q1-fueled-by-polaris-strategic-acquisitions-and-record-pipeline-despite-missing-revenue-expectations">ncreasing diversification of revenue streams</a> across verticals, including automotive, restaurants, financial services, and healthcare. 
Looking ahead, SoundHound emphasized its record pipeline, fueled by increasing demand for its advanced voice AI solutions and the growing recognition of its technological differentiation.
"We have a strong pipeline of new OEMs, and they, along with the restaurants, are very excited about our voice commerce solutions," he said.
Price Action: SOUN shares were 2.28% higher at $13 apiece in premarket on Wednesday. However, it was lower by 36.95% on a year-to-date basis and up 207.00% over a year.
Benzinga Edge Stock Rankings shows that SOUN had a stronger price trend over the short, medium, and long term. Its momentum ranking was solid at the 95.85th percentile, whereas its value ranking was poor at the 6.58th percentile; the details of all the metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="170" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09064459/SOUN-Edge-new-1024x170.png" alt="" class="wp-image-978134" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09064459/SOUN-Edge-new-1024x170.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09064459/SOUN-Edge-new-300x50.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09064459/SOUN-Edge-new-768x128.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/09064459/SOUN-Edge-new.png 1281w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were slightly higher in premarket on Wednesday. The SPY was up 0.042% at $620.60, while the QQQ advanced 0.016% to $552.43, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46271577/trumps-big-beautiful-bill-slashes-solar-incentives-cathie-woods-ark-says-nuclear-may-now-be-cheapest-option-oklo-smr-ltbr-and-other-stocks-in-focus">Trump&#8217;s Big Beautiful Bill Slashes Solar Incentives — Cathie Wood&#8217;s Ark Says Nuclear May Now Be Cheapest Option: OKLO, SMR, LTBR And Other Stocks In Focus </a></li>
</ul>
Image Via Shutterstock

SOUN

SoundHoud AI Stock Jumps Amid AI Push, But This Technical Indicator Signals Slowdown And Reversal In Rally

Wolfe Research analyst Peter Supino upgrades Fox (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) from Underperform to Peer Perform.

FOXA

Wolfe Research Upgrades Fox to Peer Perform

Wolfe Research analyst Alex Zukin initiates coverage on MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Outperform rating and announces Price Target of $280.

Comments

CIMG

Notizie

Ultime notizie per CIMG (NASDAQ:IMG) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO